Citius Oncology Explores Strategic Alternatives Ahead of LYMPHIR Commercial Launch
Commercial Launch Planned:
Citius Oncology is preparing for the commercial launch of LYMPHIR, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), in the first half of 202514.
Strategic Alternatives:
The company has engaged Jefferies LLC as its exclusive financial advisor to explore strategic alternatives, including partnerships, joint ventures, mergers, acquisitions, and licensing agreements, to maximize shareholder value5.
Market Potential:
The initial market for LYMPHIR is estimated to exceed $400 million and is growing, with potential for additional indications and combination therapies2.
Clinical Trials:
Preliminary results from an investigator-initiated Phase I clinical trial combining LYMPHIR with pembrolizumab showed promising efficacy and safety in patients with recurrent solid tumors3.
Regulatory Approval:
LYMPHIR received FDA approval in August 2024 for the treatment of adults with relapsed or refractory CTCL14.
Financial Position:
Citius Pharmaceuticals reported a decrease in cash position to $3.3 million, indicating a need for additional capital raising4.
Corporate Structure:
Citius Oncology was formed through the merger of Citius Pharmaceuticals' oncology subsidiary with TenX Keane and began trading on the Nasdaq exchange under the ticker symbol CTOR in August 202424.
Sources:
1. https://www.prnewswire.com/news-releases/citius-pharmaceuticals-and-citius-oncology-highlight-lymphir-commercial-launch-planned-for-the-first-half-of-2025-302344027.html
2. https://www.prnewswire.com/news-releases/citius-pharmaceuticals-executes-definitive-agreement-to-merge-wholly-owned-subsidiary-with-tenx-keane-acquisition-to-form-publicly-listed-citius-oncology-inc-301965379.html
3. https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-and-citius-oncology-inc-announce-promising-preliminary-results-of-an-investigator-initiated-phase-i-clinical-trial-of-pembrolizumab-keytruda-and-lymphir-in-cancer-patients-with-recurrent-solid-tu-302300516.html
4. https://www.stocktitan.net/news/CTXR/citius-pharmaceuticals-inc-reports-fiscal-full-year-2024-financial-0k52o15yusnh.html
5. https://www.prnewswire.com/news-releases/citius-oncology-engages-jefferies-as-exclusive-financial-advisor-to-explore-strategic-alternatives-302342405.html